Repligen (NASDAQ:RGEN) Updates FY 2026 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 1.970-2.050 for the period, compared to the consensus EPS estimate of 1.970. The company issued revenue guidance of $803.0 million-$833.0 million, compared to the consensus revenue estimate of $827.9 million.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several research reports. KeyCorp reissued an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Barclays boosted their price target on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday. Canaccord Genuity Group reduced their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Roth Mkm started coverage on Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 target price on the stock. Finally, Wells Fargo & Company cut their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.00.

Repligen Price Performance

Shares of RGEN stock traded up $3.80 during mid-day trading on Wednesday, hitting $129.41. 419,242 shares of the stock were exchanged, compared to its average volume of 876,499. Repligen has a 52-week low of $109.50 and a 52-week high of $175.77. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.30 billion, a PE ratio of 151.88, a price-to-earnings-growth ratio of 2.30 and a beta of 1.09. The firm has a fifty day moving average of $121.36 and a 200 day moving average of $144.51.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.Repligen’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Research analysts anticipate that Repligen will post 1.97 earnings per share for the current year.

Repligen News Roundup

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q1 results beat expectations — Repligen reported $0.48 EPS vs. a $0.38 consensus and revenue of ~$194M (+14.8% YoY), signaling continued top-line momentum and an EPS beat that supports near‑term upside. Repligen Reports First Quarter 2026 Financial Results
• Positive Sentiment: Clear FY2026 EPS guidance and multi‑year margin plan — Management set FY26 EPS of $1.97–$2.05 (in line with consensus) and announced a target to lift margins ~1 percentage point by end of 2027, which frames a path to higher profitability. Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue
• Positive Sentiment: Operational reshaping and China strategy highlighted — Management is reorganizing operations and adjusting its China footprint to improve reach and efficiency, which investors may view as proactive cost/market‑access management. Repligen Reshapes Operations And China Reach
• Neutral Sentiment: Guidance largely in line on EPS but revenue range is wide — EPS guidance matches consensus, providing clarity, while the $803–$833M revenue band gives management flexibility but leaves near‑term topline uncertainty. Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue
• Neutral Sentiment: Full earnings materials and call transcript available — The earnings call transcript and slide deck give investors more detail to model margins and product trends. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue guidance midpoint slightly below some analyst estimates — The guidance midpoint (~$818M) is modestly under the prior consensus (~$828M), which could cap upside if organic demand doesn’t accelerate. Repligen Q1 Earnings and Revenues Beat Estimates
• Negative Sentiment: Rich valuation and below‑average volume — RGEN trades at a high P/E (reflecting growth expectations) and current volume is below average, leaving the stock vulnerable to multiple compression if growth or margin improvement disappoints. Repligen shares skyrocket, what you need to know

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Measured Wealth Private Client Group LLC purchased a new stake in Repligen in the third quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter valued at about $36,000. Itau Unibanco Holding S.A. boosted its position in shares of Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the period. Johnson Financial Group Inc. acquired a new stake in Repligen in the 3rd quarter valued at approximately $65,000. Finally, Wilmington Savings Fund Society FSB lifted its stake in Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 495 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.